NCT03290950
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 18 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 43 words
- Study completion pushed from Sep 2026 to Sep 2027
- Publications: details revised at 1 of 1 entry
- Notable Results first posted: May 29, 2026
- Primary endpoint revised
- Enrollment target: 75 to 69
- Minor Primary completion date changed from estimate of Sep 2026 to May 21, 2025v22
- Notable Primary and study completion dates: Sep 2025 to Sep 2026v21
- Notable Primary and study completion dates: Sep 2024 to Sep 2025v19
Show 12 earlier versionsHide 12 earlier versions
- Notable Primary and study completion dates: Sep 2023 to Sep 2024
- Study sites revised (7)
- Notable Primary and study completion dates: Sep 2022 to Sep 2023v15
- Notable Primary and study completion dates: Sep 2021 to Sep 2022v14
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 41 to confirmed 75
- Site details revised at 7 of 7 sites
- Minor Site contacts updated at 6 of 7 sitesv11
- Notable Primary and study completion dates: Sep 2020 to Sep 2021
- Eligibility criteria revised
- Study sites: 8 to 7
- Notable Eligibility criteria expanded, about 130 words
- Study sites: 7 to 8
- Notable Primary and study completion dates: Sep 2019 to Sep 2020v8
- Minor Study sites: 6 to 7
- Interventions: carfilzomib (Drug), daratumumab (Drug), dexamethasone (Drug), lenalidomide (Drug) to carfilzomib (Drug), daratumumab (Drug), dexamethasone (Drug), dexamethasone (Drug), lenalidomide (Drug)
- Study arms: 1 to 2
- Notable Eligibility criteria revisedv4
- Notable Primary completion date: Sep 2017 to Sep 2019
- Start date changed from estimate of Sep 2017 to Sep 25, 2017
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 6 of 6 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
Drugs: daratumumab, carfilzomib, lenalidomide, dexamethasone
Sites
7 sites in 1 country